Association of serum total bilirubin with serum high sensitivity C-reactive protein in middle-aged men

Korean Journal of Family Medicine

Volumn 32, Issue 6, 2011, Pages 327-333

  Yu, Kiwoong ^a   Kim, Cheolhwan ^a   Sung, Eunju ^a   Shin, Hocheol ^a   Lee, Hyewon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Bilirubin; Cardiovascular disease; High sensitivity C reactive protein

Indexed keywords

EID: 83655164582     PISSN: 20056443     EISSN: 20926715     Source Type: Journal    
DOI: 10.4082/kjfm.2011.32.6.327     Document Type: Article

References (27)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
2. Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J 2000;140:324-8.
3. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109:2818-25.
4. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
5. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-11.
6. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of infl ammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
7. Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 1994;40:18-23.
8. Hunt SC, Wu LL, Hopkins PN, Williams RR. Evidence for a major gene elevating serum bilirubin concentration in Utah pedigrees. Arterioscler Th romb Vasc Biol 1996;16:912-7.
9. Moon JS, Chang WJ, Lee CH, Lee JE, Chun KA, Yoon JS, et al. Relationship between serum bilirubin levels and coronary atherosclerosis in patients with type 2 diabetes. Korean Diabetes J 2008;32:338-45.
10. Libby P, Ridker PM. Infl ammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004;116 Suppl 6A:9S-16S.
11. Djousse L, Levy D, Cupples LA, Evans JC, D'Agostino RB, Ellison RC. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol 2001;87:1196-200.
12. Djousse L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Effect of serum albumin and bilirubin on the risk of myocardial infarction (the Framingham Offspring Study). Am J Cardiol 2003;91:485-8.
13. Perlstein TS, Pande RL, Creager MA, Weuve J, Beckman JA. Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999-2004. Am J Med 2008;121:781-8.
14. Novotny L, Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood) 2003;228:568-71.
15. Vitek L, Jirsa M, Brodanová M, Kalab M, Marecek Z, Danzig V, et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 2002;160:449-56.
16. Nakanishi N, Shiraishi T, Wada M. Association between fasting glucose and C-reactive protein in a Japanese population: the Minoh study. Diabetes Res Clin Pract 2005;69:88-98.
17. Nah EH, Lee JK. The relationship between high sensitivity C-reactive protein and metabolic syndrome according to the fasting glucose level at medical checkups. Korean J Lab Med 2006;26:454-9.
18. Jo YH, Choi EY, Cheong YS, Park EW, Kim JH. Association between alcohol consumption and hsCRP in Korean adults. J Korean Acad Fam Med 2007;28:768-73.
19. Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and plasma concentration of C-reactive protein. Circulation 2003;107:443-7.
20. Imhof A, Froehlich M, Brenner H, Boeing H, Pepys MB, Koenig W. Effect of alcohol consumption on systemic markers of infl ammation. Lancet 2001;357:763-7.
21. Van Hoydonck PG, Temme EH, Schouten EG. Serum bilirubin concentration in a Belgian population: the association with smoking status and type of cigarettes. Int J Epidemiol 2001;30:1465-72.
22. Madhavan M, Wattigney WA, Srinivasan SR, Berenson GS. Serum bilirubin distribution and its relation to cardiovascular risk in children and young adults. Atherosclerosis 1997;131:107-13.
23. Chin HJ, Song YR, Kim HS, Park M, Yoon HJ, Na KY, et al. Th e bilirubin level is negatively correlated with the incidence of hypertension in normotensive Korean population. J Korean Med Sci 2009;24(Suppl 1):S50-6.
24. Wu TW, Fung KP, Wu J, Yang CC, Weisel RD. Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem Pharmacol 1996;51:859-62.
25. Ollinger R, Bilban M, Erat A, Froio A, McDaid J, Tyagi S, et al. Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation. Circulation 2005;112:1030-9.
26. Ollinger R, Yamashita K, Bilban M, Erat A, Kogler P, Thomas M, et al. Bilirubin and biliverdin treatment of atherosclerotic diseases. Cell Cycle 2007;6:39-43.
27. Neuzil J, Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem 1994;269:16712-9.